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PC-15: Cerebral Glucose Hypometabolism in Tick-Borne Encephalitis, a Pilot Study in 10 Patients

**Anelia Dietmann, Daniel Putzer, Ronny Beer, Raimund Helbok, Bettina Pfausler, Abdul Jalil Nordin, Irene Virgolini, Astrid E. Grams, Erich Schmutzhard**

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria

**Background:** Tick borne encephalitis (TBE) is an acute meningoencephalitis with or without myelitis caused by an RNA virus from the flavivirus family transmitted by Ixodes spp ticks. The neurotropic TBE virus infects preferentially large neurons in basal ganglia, anterior horns, medulla oblongata, purkinje cells and thalamus. Brain metabolic changes related to radiologic and clinical findings have not been described so far.

**Methods:** Here we describe the clinical course of 10 consecutive TBE patients with outcome assessment at discharge and after 12 month using a modified Rankin Scale. Patients underwent cerebral MRI after confirmation of diagnosis and before discharge. 18F-FDG PET/CT scans were performed within day 5 to day 14 after TBE diagnosis. Extended analysis of coagulation parameters by thrombelastometry (ROTEM^®^ InTEM, ExTEM, FibTEM) was performed every other day after confirmation of TBE diagnosis up to day 10 after hospital admission or discharge.

**Results:** All patients presented with a meningoencephalitic course of disease. Cerebral MRI scans showed unspecific findings at predilection areas in three patients. 18F-FDG PET/CT showed increased glucose utilization in one patient and decreased 18F.FDG uptake in seven patients. Changes in coagulation measured by standard parameters and thrombelastometry were not found in any of the patients.

**Discussion:** Glucose hypometabolism was present in 7 out of 10 TBE patients reflecting neuronal dysfunction in predilection areas of TBE virus infiltration responsible for development of clinical signs and symptoms.
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PC-16: 18F-DOPA in Brain Tumors Under Proton Therapy

**Franca Chierichetti**
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Aim of the Study: Proton therapy (PRT) is an advanced RT modality with a unique dose-deposition pattern that allows for treatment of a target volume reducing scatter dose delivered to normal tissues, respect to conventional photon RT. The aim of this study was to assess, for primary brain tumors, the potential role of 18F.DOPA PET/CT to better define PRT planning.

**Methods:** According to a joint decision with proton radiation oncologist, both high grade gliomas (especially glioblastoma) and low grade ones, already submitted to surgery for total or partial resection of the lesion, were studied by 18F-DOPA PET/CT. 18F-FDG PET/CT was also performed in selected cases to better assess tissue heterogeneity inside the tumor, to potentially deliver modulated radiation fields, following the concept of dose painting. Functional data were provided to radiation oncologist that compared them to the standard ones, as established just by morphological MRI. Therefore, two dose paintings by contours (DPBC), for dose escalation, were assessed.

**Results:** 18F-DOPA PET/CT changed the expected planning, as determined just by MRI, in more than half of patients, regardless of grading. 18F-FDG and Abstracts . Pre-conference International Symposium on Nuclear Neurology 18F-DOPA PET/CT studies provided, in high grade gliomas, different and complementary data about the behavior of primary brain tumors, respect to anatomical imaging and changed the standard contouring in the target delineation for PRT, determining boost sub volumes in the overall planned area of treatment. 18F-FDG PET/CT was useful to evaluate the function of normal brain tissue both near and distant to the tumor, too.

**Conclusions:** Even if PRT is quite a new modality, there are published data, especially in young people, showing its potential role for a better quality of life, respect to conventional radio treatment, as spares normal tissues. Recent trials are also investigating if its reduced doses of radiation on brain may be relevant to decrease not only the risk of a second cancer, but subsequent cognitive impairment, too. Our experience started 4 months ago and, up to now, we do not have enough data about the impact of this technique as an improvement in radiation outcome, but we can argue that a personal dose painting both for high and low grade tumors may be more efficacy for survival, respect to standard planning, and 18F-DOPA PET/CT proved to be the better modality for dose painting. Moreover, we may expect that the overall information (18F.DOPA and 18F-FDG PET/ CT) provided in high grade gliomas will be an useful approach not only for a better result in cancer control, but also for a better quality of life.
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